Cell populations which co-express CD49c and CD90
First Claim
1. A substantially homogenous cell population which co-express CD49c, CD90 and telomerase.
2 Assignments
0 Petitions
Accused Products
Abstract
Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.
194 Citations
96 Claims
- 1. A substantially homogenous cell population which co-express CD49c, CD90 and telomerase.
- 14. A substantially homogenous cell population with co-express CD49c and CD90, but does not express bone sialoprotein.
-
27. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 100 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90. - View Dependent Claims (42, 43)
-
-
44. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.
-
-
45. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm2 under a low oxidative stress condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.
-
-
46. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 75,000 cells/cm2 under a low oxidative stress condition to produce an adherent cell population;
b) culturing the adherent cell population at a seeding density of less than about 100 cells/cm2 under a low oxidative stress condition; and
c) selecting from the cultured adherent cell population, cells which co-express CD49c and CD90.
-
-
47. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 50 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.
-
-
48. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 30 cells/cm2 under a low oxygen condition; and
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90.
-
-
49. A method of making a substantially homogenous cell population which co-express CD49c and CD90, comprising the steps of:
-
a) culturing a source of the cell population at a seeding density of less than about 75,000 cells/cm2 under a low oxygen condition to produce an adherent cell population;
b) culturing the adherent cell population at a seeding density of less than about 100 cells/cm2 under a low oxygen condition; and
c) selecting from the cultured adherent cell population, cells which co-express CD49c and CD90. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)
-
-
61. A method of treating a human suffering from a degenerative or acute injury condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c and CD90.
- 62. A method of treating a human suffering from a neurological condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c and CD90.
-
64. A method treating a human suffering from a cardiac condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c and CD90.
-
65. A method of treating a human suffering from a neurological condition, comprising the steps of:
-
a) culturing a source of a cell population at a seeding density of less than about 100 cells/cm2 under a low oxygen condition;
b) selecting from the cultured source of the cell population, a population of cells which co-express CD49c and CD90; and
c) administering the population of cells which co-express CD49c and CD90 to the human. - View Dependent Claims (66, 67, 68, 69, 70, 71, 72)
-
-
73. A method of making a committed progenitor cell, comprising the steps of:
-
a) culturing a source of a cell population;
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90; and
c) modifying the cells which co-express CD49c and CD90 to become committed progenitor cells. - View Dependent Claims (74, 75, 76, 77)
-
-
78. A method of treating a human suffering from a degenerative or acute injury condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c, CD90 and telomerase.
-
79. A method of treating a human suffering from a neurological condition, comprising the steps of:
-
a) culturing a source of a cell population;
b) selecting from the cultured source of the cell population, cells which co-express CD49c and CD90;
c) modifying the cells which co-express CD49c and CD90 to become a committed progenitor cell; and
d) administering the committed progenitor cell to the human. - View Dependent Claims (80, 81, 82, 83, 84, 85, 86, 87)
-
- 88. A pharmaceutical composition comprising a substantially homogeneous cell population which co-express CD49c and CD90.
-
93. A pharmaceutical composition comprising a substantially homogeneous cell population which co-express CD49c, CD90 and telomerase.
-
94. A method of treating a human suffering from a neurological condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c, CD90 and telomerase.
-
95. A method of treating a human suffering from a degenerative or acute injury condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c, CD90 and a bone lineage marker.
-
96. A method of treating a human suffering from a neurological condition, comprising the step of administering to the human a substantially homogenous cell population which co-express CD49c, CD90 and a bone lineage marker.
Specification